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in the experimental group of animals. One group was implanted with autologous 
tissue grafts engineered from scaffold and articular chondrocytes. In one group cell 
free scaffolds were implanted while last group served as negative control in which 
only conversion of defect was performed, but it was left untreated. Animals were 
sacrificed and tissue analysis was performed at three different time points: 6 weeks, 
3 months and 12 months after the implantation. Tissue analysis included macrosco-
pic, microscopic and molecular evaluation. Microscopic analysis included different 
stains (hematoxylin-eosin, safranin O, picrosirius) and immunohistochemistry (co-
llagen I, II and aggrecan). Semi-quantitative data of morphology were obtained with 
histological score ICRS II. ELISA and DMMB assays were performed to quantify the 
amount of collagen I, II and glycosaminoglycans in repair tissue. 
Results confirmed the feasibility of production of autologous cartilage tissue 
grafts from nasal septum chondrocyte for treatment of condyle cartilage defects. 
Furthermore, nasal chondrocyte grafts showed promising results in restoration of 
damaged articular cartilage. 
The research leading to these results has received funding from the Europe-
an Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement 
n°278807 BIO-COMET. 
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Purpose 
As compared to commonly used cell based treatments for articular cartilage repair, 
grafting of cartilage tissues, engineered in vitro to reach a mature stage, could result 
in more durable repair. To reduce the variability in the quality of the engineered tissue 
grafts, nasal chondrocytes were used as a cell source with reproducible chondrogenic 
capacity. The purpose of this phase-1 study was to demonstrate safety and feasibility of 
the procedure. Preliminary indications on efficacy after 12 months are also presented. 
Material and methods 
Ten patients with symptomatic, post-traumatic full-thickness cartilage lesions 
(2-8cm2) on the femoral condyle/ trochlea were treated. Patients underwent nasal 
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septum cartilage biopsy in an outpatient procedure. Autologous nasal chondrocytes 
were isolated, expanded, seeded and cultured in collagen sponges (Chondrogide®, 
Geistlich) according to Good Manufacturing Practice (GMP) regulations. After four 
weeks production, the engineered nasal cartilage graft was implanted via mini-ar-
throtomy. 
Patients were followed up radiologically by MRI (MOCART score), delayed Ga-
dolinium Enhanced MRI (dGEMRIC, for assessment of glycosaminoglycans con-
tent) and clinically (IKDC score). 
Results 
No complications occurred by nasal cartilage biopsying or implantation of the 
engineered tissues, 
10 patients with 12 cartilage defects reached 12 months follow up so far. One 
patient with 1 defect partially lost the graft due to new sports injury and was exc-
luded from analysis. The MOCART score 12 months post-surgery was 41.3 (5-60). 
The dGEMRIC revealed a relative ΔR1 of 1.40 (0.78-2.17). The IKDC pre-surgery and 
12 months post-surgery was 46.5 and 75.6 respectively. The KOOS pre-surgery and 
12 months post-surgery was 63.9 and 81.3 (Symptoms), 70.4 and 88.9 (Pain), 76.1 and 
93.2 (ADL), 36.1 and 69.4 (Sport), 41.7 and 57.0 (QoL). 
Conclusion 
These early results demonstrate safety and feasibility of the method and indicate that 
engineered nasal cartilage grafts can participate to the repair of articular cartilage defects in 
the knee. The mean relative ΔR1 of 1.40 (1.0 for native cartilage) suggests that hyaline repair 
tissue can be achieved, possibly to a higher extent than MACT (2.18, Trattnig+, 2008) or ACT 
(2.40, Trattnig+, 2007). Our results demonstrate safety and feasibility of the method and indi-
cate that patients can benefit from this therapy. 
This study opens a new approach in biological cartilage regeneration, based on 
engineering of mature cartilage tissues using autologous nasal chondrocytes. 
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